John Sourbeer

Stock Analyst at UBS

(0.7)
# 2530
Out of 5,441 analysts
55
Total ratings
Success rate
Average return
19 Stocks
Name Action PT Current % Upside Ratings Updated
QGEN Qiagen
Maintains: Neutral
48 50
48.01 4.14% 5 Aug 7, 2025
WST West Pharmaceutical ...
Maintains: Strong Buy
285 320
240.33 33.15% 4 Jul 25, 2025
ICLR Icon
Maintains: Strong Buy
170 240
159.85 50.14% 2 Jul 25, 2025
CYRX CryoPort
Maintains: Strong Buy
10 11
8.1 35.8% 6 Apr 1, 2025
STVN Stevanato Group
Maintains: Neutral
24 24
21.8 7.8% 2 Mar 7, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
43 45
23.65 90.27% 4 Feb 13, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
2
1.25 60% 3 Nov 11, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
133 145
94.79 52.97% 3 Nov 5, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
12 15
20.01 -25.04% 2 Mar 20, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
452 480
449.72 6.73% 4 Mar 8, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
7 8
1.29 481.4% 2 Mar 5, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
94 102
30.8 231.17% 3 Mar 1, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
58 64
63.48 0.03% 6 Feb 6, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
7 3
n/a n/a 2 Oct 12, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Neutral
50
12.31 306.17% 1 Feb 2, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Neutral
68
42.98 58.21% 1 Sep 7, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
142 128
131.33 -2.54% 2 Jul 27, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
13 4
2.43 64.61% 2 Mar 24, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
23
17.63 30.46% 1 Feb 22, 2021